Radiotherapy for extensive-stage small-cell lung cancer in the immunotherapy era

Currently, chemoimmunotherapy is the first-line treatment for extensive-stage small-cell lung cancer (ES-SCLC). However, only 0.8%–2.5% of the patients presented complete response after chemoimmunotherapy. Considering that ES-SCLC is highly sensitive to radiotherapy, the addition of radiotherapy aft...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Huanhuan, Zhao, Yangzhi, Ma, Tiangang, Shao, Hao, Wang, Tiejun, Jin, Shunzi, Liu, Zhongshan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10493776/
https://www.ncbi.nlm.nih.gov/pubmed/37701437
http://dx.doi.org/10.3389/fimmu.2023.1132482

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10493776/
https://www.ncbi.nlm.nih.gov/pubmed/37701437
http://dx.doi.org/10.3389/fimmu.2023.1132482

Ejemplares similares